Inventiva (IVA) Other Accumulated Expenses (2018 - 2025)
Inventiva (IVA) posted quarterly Other Accumulated Expenses of $17.2 billion for Q2 2025, up 273225.25% year-over-year from N/an in Q2 2024, and up 86.86% quarter-over-quarter from $9.2 billion in Q4 2024.
Analysis
Inventiva (IVA) Other Accumulated Expenses (2018 - 2025) Analysis & Trends
Inventiva's Other Accumulated Expenses history runs 7 years deep, the most recent figure standing at $17.2 billion for Q2 2025.
- In Q2 2025, Other Accumulated Expenses rose 273225.25% year-over-year to $17.2 billion; the TTM figure through Jun 2025 stood at $17.2 billion (up 273225.25% YoY), while the FY2024 annual figure was $9.2 billion, up 119108.59% from the prior year.
- Other Accumulated Expenses for Q2 2025 stood at $17.2 billion, up from $9.2 billion in the prior quarter.
- The five-year high for Other Accumulated Expenses was $17.2 billion in Q2 2025, with the low at $5.4 million in Q2 2023.
- The 5-year median for Other Accumulated Expenses is $8.2 million (2023), against an average of $3.9 billion.
- The sharpest annual moves came in 2022 and 2025: Other Accumulated Expenses slumped 99.93% in 2022, then surged 273225.25% in 2025.
- Inventiva's Other Accumulated Expenses stood at $7.8 billion in 2021, then plunged by 99.93% to $5.6 million in 2022, then soared by 37.76% to $7.7 million in 2023, then surged by 119108.59% to $9.2 billion in 2024, then jumped by 86.86% to $17.2 billion in 2025.
- Business Quant data shows IVA's Other Accumulated Expenses at $17.2 billion in Q2 2025, $9.2 billion in Q4 2024, and $6.3 million in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Inventiva | 893.85 Mn | 893.85 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 20.93 Mn |
| Jun 30, 2025 | 17.17 Mn |
| Dec 31, 2024 | 9.19 Mn |
| Jun 30, 2024 | 6.25 Mn |
| Dec 31, 2023 | 7.71 Mn |
| Jun 30, 2023 | 5.42 Mn |
| Dec 31, 2022 | 5.60 Mn |
| Jun 30, 2022 | 5.01 Mn |
| Dec 31, 2021 | 7.77 Mn |
| Jun 30, 2021 | 5.43 Mn |
| Mar 31, 2021 | 8.71 Mn |
| Dec 31, 2020 | 8.15 Mn |
| Jun 30, 2020 | 5.88 Mn |
| Mar 31, 2020 | 6,623.63 |
| Dec 31, 2019 | 5.53 Mn |
| Dec 31, 2018 | 5.56 Mn |